X4 Pharmaceuticals director receives 110,000 share option grant

X4 Pharmaceuticals director Kelly Gold received a stock option grant as part of compensation.

Rhea-AI Filing Summary

X4 Pharmaceuticals director Kelly Gold received a stock option grant as part of compensation. The award covers 110,000 shares of common stock with an exercise price of $4.085 per share and expires on July 1, 2036. According to the disclosure, these options were granted at no cost on the grant date and will vest in full on the one-year anniversary of the grant date, as long as Gold continues providing services through that date. Following this award, Gold is reported to hold stock options covering 110,000 shares directly.

Insider Trade Summary

Grant/Award: 110,000 shares

Grant/Award 1 txn

Insider Gold Kelly

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	110,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 110,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option shall vest in full on the one-year anniversary of the grant date, subject to the Reporting Person continuing to provide services through such date.

Key Figures

Option shares granted: 110,000 shares Exercise price: $4.085 per share Post-grant option holdings: 110,000 shares +2 more

5 metrics

Option shares granted 110,000 shares Stock option award to director on grant date

Exercise price $4.085 per share Strike price of newly granted options

Post-grant option holdings 110,000 shares Total option shares held following transaction

Option expiration date July 1, 2036 Expiration of the stock option grant

Vesting schedule 100% after one year Vests on one-year anniversary of grant if services continue

Key Terms

Stock Option (right to buy), exercise price, vest in full, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price": "4.0850""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"The shares subject to the option shall vest in full on the one-year anniversary"

expiration date financial

"expiration_date": "2036-07-01T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

derivative securities financial

"transaction_type": "derivative""

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did XFOR director Kelly Gold report in this Form 4 filing?

Kelly Gold reported receiving a stock option grant for 110,000 XFOR shares. The options were awarded as compensation, giving the right to buy common stock at a preset exercise price if vesting conditions are met.

How many X4 Pharmaceuticals (XFOR) shares are covered by the new option grant?

The option grant covers 110,000 shares of X4 Pharmaceuticals common stock. These are not current share purchases but rights to buy shares in the future at a fixed exercise price if the options vest.

What is the exercise price of Kelly Gold’s X4 Pharmaceuticals stock options?

The exercise price of the stock options is $4.085 per share. This means Gold can buy up to 110,000 XFOR shares at $4.085 each once the options vest and before they expire, regardless of future market price.

When do Kelly Gold’s XFOR stock options vest and expire?

The options vest in full on the one-year anniversary of the grant date. Vesting requires Gold to continue providing services through that date, and the options expire on July 1, 2036 if not exercised earlier.

How many XFOR stock option shares does Kelly Gold hold after this grant?

After this grant, Gold holds stock options covering 110,000 shares of X4 Pharmaceuticals common stock. This reflects the new award reported and is shown as directly owned derivative securities in the Form 4.

Is Kelly Gold’s transaction in X4 Pharmaceuticals shares a market purchase or sale?

The transaction is not a market purchase or sale; it is a grant of stock options. These options were awarded at no cost on the grant date and give a future right to buy shares at a fixed exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gold Kelly

(Last) (First) (Middle)

C/O X4 PHARMACEUTICALS, INC.

61 NORTH BEACON STREET, 4TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02134

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
X4 Pharmaceuticals, Inc [ XFOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.085	07/01/2026		A		110,000		(1)	07/01/2036	Common Stock	110,000	$0	110,000	D

Explanation of Responses:

1. The shares subject to the option shall vest in full on the one-year anniversary of the grant date, subject to the Reporting Person continuing to provide services through such date.

Remarks:

	/s/ David Kirske, Attorney-In-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)